4.8 Review

Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 13, Issue 9, Pages 692-708

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4308

Keywords

-

Funding

  1. US National Institutes of Health (NIH) [U01 MH087956, R01 MH062646, R01 MH073676, U19 MH097056, R01 NS031373, P50 NS071669, R01 DA023947, R01 MH082867, U54 MH084659]
  2. NIH [R01 GM080403, R01 MH090192, R01 GM099842, R01 DK097376, R21 NS078262]
  3. NSF [0742762, CHE 1305874]
  4. International Rett Syndrome Foundation
  5. Autism Speaks

Ask authors/readers for more resources

Novel allosteric modulators of G protein-coupled receptors (GPCRs) are providing fundamental advances in the development of GPCR ligands with high subtype selectivity and novel modes of efficacy that have not been possible-with traditional approaches. As new allosteric modulators are advancing as drug candidates, we are developing an increased understanding of the major advantages and broad range of activities that can be achieved with these agents through selective modulation of specific signalling pathways, differential effects on GPCR honnodinners versus lieterodinners, and other properties. This understanding creates exciting opportunities, as well as unique challenges, in the optimization of novel therapeutic agents for disorders of the central nervous system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available